A Safety Extension Study of Ontamalimab in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)
Completed · Phase 3 · NCT03283085
Conditions: Crohn's Disease, Ulcerative Colitis
At a glance
- Research payments reported, 2025
- $8,611
- U.S. investigators named
- 4
- Sites paid
- 4
- Planned or actual enrollment
- 557
About the trial
- Sponsor
- Shire
- Tested
- 25 mg Ontamalimab (drug), 75 mg Ontamalimab (drug)
- Dates
- Started 2018-02-27; completion 2023-12-13
- Results posted
- Yes
The purpose of this study is to evaluate the safety and tolerability of long-term treatment with ontamalimab in participants with moderate to severe Ulcerative Colitis (UC) or Crohn's disease (CD)
From ClinicalTrials.gov, last updated 2024-06-21. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Takeda Pharmaceuticals U.S.A., Inc. reported $8,611 in research payments for this study in 2025 (17 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Kwabena Ayesu, MD Internal Medicine · Orlando, FL
- Robert Benish, M.D. Gastroenterology · Palm Bay, FL
- Mark R. Fleisher Gastroenterology · Jacksonville, FL
- Khurram M. Baig, DO Gastroenterology · Winchester, VA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Mid-Atlantic Health Specialist $3,878
- Encore Borland Groover Clinical Research LLC $2,058
- Valley Health Systems $2,015
- Omega Research Orlando LLC $660
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.